The hallmarks of aging · Where the damage starts

DNA damage

Scientific name: Genomic instability

Your DNA is damaged thousands of times a day, in every cell, at every age. Repair systems fix almost all of it, but with age they slow down and make more mistakes, so permanent errors slowly build up.

Measurable today: mostly in research labs. One blood test catches part of the picture.

Why it matters

Why it matters to you

The damage is normal. Falling behind on repair is the aging part.

Young, healthy cells take thousands of hits a day too. What mainly changes with age is how well the repair keeps up.

It sits at the start of the chain.

Damage that is not repaired can make a cell stop dividing for good, die, or edge toward cancer. Those outcomes feed several of the other aging drivers.

Errors in blood stem cells can be seen and counted.

With age, one blood stem cell carrying a mutation can grow into a large family of cells. That pattern, called CHIP, is linked to blood cancer and to heart disease.

Measurement

Can it be measured?

CHIP testing (clonal hematopoiesis)

Specialist and research labs

What it showsWhether a family of blood stem cells carrying the same mutation has grown large. It turns up in about 1 in 10 people tested in their 70s, and more often after that.

LimitsIt covers blood cells only. Most people who have it never develop a blood cancer, and there is no proven treatment for it.

Sources: PubMed 25426837, PubMed 25931582

Oxidative DNA damage marker (8-OHdG) in urine or blood

Some specialty labs

What it showsA by-product released when one common kind of DNA damage is repaired.

LimitsIt is not a steady reading of your overall damage. It shifts with recent diet, exercise, and the lab method, and it covers only one kind of damage.

DNA break and mutation-counting lab methods

Research only

What it showsHow many DNA breaks or mutations sit in a blood or tissue sample, using methods such as break markers, the comet assay, and highly accurate DNA sequencing.

LimitsThere is no standardized result for one person yet. These are tools for studies, with no agreed normal ranges.

Biological-age tests (epigenetic clocks) measure a different aging driver, the chemical settings on your genes, not DNA damage.

What would make it measurable

  • Highly accurate DNA sequencing that counts rare mutations in a blood sample, made cheap and standardized.
  • Blood tests for DNA breaks and repair speed with agreed normal ranges.
  • Proof that lowering these numbers means healthier aging, the step every one of these markers still needs.
What can be done

What can be done about it?

Fifteen items in our catalog have human studies that support an effect on DNA damage, almost all by turning up the body's own antioxidant defenses. None has been shown to make people age more slowly, because no DNA-damage test has been proven to track aging yet.

Three examples from our catalog, rotated daily: one with stronger evidence here, one with early evidence, and one where we found none. A sample, not a ranking or a recommendation. Ratings as of October 25, 2026. What the evidence levels mean.

Botanical

Gotu Kola

Evidence for DNA damage: Supported

Human studies support it engaging this aging driver, short of the strongest trial designs.

Amino Acids & Derivatives

Glutathione

Evidence for DNA damage: Emerging

Only early or animal-stage evidence for this aging driver so far.

Gut & Fiber

Inulin

Evidence for DNA damage: None found

We did not find qualifying evidence that it engages this aging driver.

Its stronger evidence is for gut microbe imbalance.

See the full picture for your own routine

The Longevity Intelligence Report shows how what you take and do covers DNA damage and the other hallmarks. Members also see every item in our catalog ranked by the strength of its evidence for DNA damage. Opens in December.

Get early access
New research

New studies on DNA damage

Picked for what they add to the biology, and to the chance of one day treating it, in plain words. Research checked October 2, 2026.

DNA damage

Eating less slowed the buildup of DNA mutations in mice

Mice · Cell · September 9, 2026

What they foundMice on a calorie-restricted diet built up fewer DNA mutations in liver, kidney, and brain cells than normally fed mice, counted with a very accurate DNA-reading method.

What it does not showMice only. It does not show the mice lived longer because of it, or that people would respond the same way.

Why it mattersMutations piling up in body cells is one of the most upstream drivers of aging. This shows the pace can change, at least in mice.

Read the study on PubMed ↗
Caloric restriction modulates genome-wide somatic mutation in mice.
DNA damage

A blood-cell mutation common with age tracked worse heart, kidney, and metabolic health

People, 451,460 UK adults followed for about 13 years · European Heart Journal · August 30, 2026

What they foundAbout 3 in 100 people carried CHIP. Over 13 years, carriers were more likely to reach the most advanced stage of combined heart, kidney, and metabolic disease, and blood proteins tied to inflammation tracked the risk.

What it does not showAn association in one population. It cannot show that CHIP causes the disease, and CHIP itself has no proven treatment.

Why it mattersCHIP is one of the few DNA changes of aging a blood test can detect today, and this adds to evidence that it matters well beyond blood cancer.

Read the study on PubMed ↗
Clonal haematopoiesis and cardiovascular-kidney-metabolic syndrome: a cohort study.
DNA damage

A brake on DNA repair may help set how fast mutations build up

Mice, 92 mammal species, and human brain data · Nature Aging · June 2, 2026

What they foundDREAM is a group of proteins that holds back DNA-repair genes. Where it was less active, mutations built up more slowly, and longer-lived mammal species had less of it. Mice without DREAM built up modestly fewer brain mutations.

What it does not showNot tested in people, the effect in mice was modest, and releasing a brake on repair could carry its own risks.

Why it mattersIt points to a specific switch that may set how well repair keeps up with age, the kind of target a future treatment would need.

Read the study on PubMed ↗
DREAM repressive activity links somatic mutation, lifespan and disease.

Follow the research on DNA damage

Pick the ones you want to follow. Starting in December, we'll email you every two weeks when new studies or new tests come out on them. Longevity Intelligence Report members also get the plain-English read on each one: why it matters, and whether it should change what you're doing.

Free, no account needed. We keep your email and the topics you pick, nothing else. Unsubscribe anytime.

From the articles

Articles on DNA damage

Go deeper

Connected hallmarks

How the biology works

Damage comes from inside and outside the cell. Reactive oxygen species (unstable oxygen byproducts of normal energy production in the mitochondria) chemically nick and oxidize DNA, while ultraviolet light, radiation, and environmental chemicals add their own hits, and the simple act of copying DNA before a cell divides introduces replication errors. The two most serious lesions are single-strand breaks (a cut in one of the two DNA strands) and double-strand breaks (both strands severed at once), the latter being the hardest to repair correctly.

Cells run several distinct repair crews, each tuned to a different kind of damage. Base excision repair (BER) swaps out a single chemically altered DNA letter; nucleotide excision repair (NER) cuts out a short stretch around bulkier distortions such as sunlight-induced damage; and double-strand breaks are mended either by homologous recombination (HR), an accurate method that copies the missing information from the cell's second, intact copy of the chromosome, or by non-homologous end joining (NHEJ), a faster but error-prone method that simply glues the broken ends back together. NHEJ is quick but can leave small scars, which is one way mutations creep in.

Damage-sensor proteins called ATM and ATR act as alarm bells. When they detect breaks they activate a master switch protein, p53, which pauses the cell (often through a stop protein called p21) to buy time for repair, or, if the damage is too severe, orders the cell to self-destruct or to enter senescence (a permanent non-dividing state). This decision point is the cell's core quality-control checkpoint.

When repair fails, lags behind, or the checkpoints are bypassed, mutations become permanent and can stack up into chromosomal instability, meaning whole chunks of chromosomes get lost, duplicated, or rearranged. In blood-forming cells this shows up as clonal hematopoiesis, where a single mutated stem cell quietly expands into a large family of cells carrying the same mutation, a process linked to both blood cancers and cardiovascular risk.

The genome inside the mitochondria (the cell's power plants carry their own small loop of DNA) is especially exposed, because it sits right next to the reactive byproducts of energy production and has weaker repair machinery than the main genome in the nucleus. Mitochondrial DNA damage feeds back into worse energy production and more reactive byproducts, tying genomic instability tightly to mitochondrial decline.

Where treatment research is heading
Next few years

Clonal hematopoiesis screening (CHIP blood panels)

Sequencing-based blood tests can now spot expanding clones of mutated blood cells carrying changes in genes such as DNMT3A, TET2, and JAK2. These clones flag elevated risk of blood cancer and, strikingly, of cardiovascular disease, turning a previously invisible genomic process into something measurable in a routine tube of blood.

Not ready yet: Finding a clone does not yet come with a proven treatment, so for most people a positive result raises anxiety without a clear action, and screening guidelines for healthy adults do not exist.

Better DNA-damage and genome-instability biomarkers

Research groups are working to turn lab assays like gamma-H2AX foci, the comet assay, and somatic-mutation counts into standardized, blood-based tests, which would finally let trials and individuals see whether anything is actually lowering genomic damage.

Not ready yet: None of these is yet validated and standardized for routine human use, so today there is no reliable way to put a number on a person's genome-wide damage burden or to track it over time.

Further out

DNA-repair-enhancing therapeutics via the NAD+ axis

Repair enzymes called PARPs and sirtuins both run on NAD+ (a coenzyme that falls with age), so compounds that raise NAD+, including nicotinamide riboside and NMN, aim to keep the repair crews better staffed. Early work suggests restoring NAD+ can improve the activity of these repair pathways in aged cells and animals.

Not ready yet: Human evidence that NAD+ boosting actually reduces DNA damage or improves aging outcomes is still early and inconsistent, and PARP activity is a double-edged sword the body tightly regulates for good reason.

Senolytics that selectively clear DNA-damaged cells

Cells with heavy, unrepairable DNA damage often become senescent. Senolytic drugs such as the dasatinib-plus-quercetin combination and the flavonoid fisetin aim to remove these damaged cells, lowering the burden of mutation-carrying, inflammation-spreading cells in a tissue.

Not ready yet: Senolytic human data are early and short, the right targets and doses are unsettled, and clearing the wrong cells could impair normal repair and wound healing.

Long shots

Genome-maintenance gene therapy and in-vivo DNA-repair enhancement

If the genes encoding repair crews or the nuclear scaffolding (the lamina) could be safely topped up or tuned inside living tissue, it might be possible to slow the accumulation of damage rather than just react to it, an idea inspired by long-lived species that appear to invest more heavily in genome maintenance.

Not ready yet: Safely delivering and dosing such therapies across the whole body is unsolved, and pushing repair pathways too hard carries its own cancer and toxicity risks.

In-vivo base and prime editing to correct accumulated mutations

CRISPR-derived base and prime editors can rewrite specific DNA letters without cutting both strands, hinting at a future where individual damaging mutations could be corrected inside the body, including the inherited mutations behind progeroid (accelerated-aging) syndromes.

Not ready yet: Delivery, off-target edits, and the sheer number of scattered, cell-by-cell somatic mutations make genome-wide correction a distant, high-risk goal; today's editing is realistic only for single, well-defined mutations.

Facts and sources on this page checked October 2, 2026. This page explains research. It is not medical advice or a recommendation to take anything. How we grade the evidence.